search
Back to results

MVA to Improve the Pregnancy Outcome in Aged Infertility Women With Assisted Reproductive Technology

Primary Purpose

Infertility, Female, IVF, Reproductive Disorder

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Mevalproic acid
Sponsored by
Nanjing University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility, Female

Eligibility Criteria

38 Years - 42 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: 38 years ≤ age ≤ 42 years; Number of IVF/ICSI cycles ≤ 2 Exclusion Criteria: Egg donor cycle Chromosome abnormality; Adenomyosis, hysteromyoma, thin endometrium, endometriosis and other uterine diseases; Patients with repeated implantation failure

Sites / Locations

  • Reproductive Medicine Center, The affiliated Drum Towel Hospital of Nanjing University Medical SchoolRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

MVA treated group

Control group

Arm Description

Oocytes in this groups will be cultured with MVA

Oocytes in this groups will be culture without MVA

Outcomes

Primary Outcome Measures

Embryo haploid rate
Preimplantation genetic testing (PGT) was used to test embryo haploid rate

Secondary Outcome Measures

Full Information

First Posted
March 13, 2023
Last Updated
March 28, 2023
Sponsor
Nanjing University
search

1. Study Identification

Unique Protocol Identification Number
NCT05788822
Brief Title
MVA to Improve the Pregnancy Outcome in Aged Infertility Women With Assisted Reproductive Technology
Official Title
A Single-center Randomized Controlled Trial on Mevalproic Acid Improving Oocyte Quality and Embryo Development in Elderly Infertile Patients
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 8, 2022 (Actual)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
December 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Nanjing University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this clinical trial is to test MVA on improving pregnancy outcome in elderly infertile patients undergoing invitro fertilization (IVF). The main question it aims to answer is whether MVA could improve embryo haploid rate. Participants requested IVF are asked to randomly culture equal numbers of oocyte and embryo with or without MVA. Therefore, sibling oocytes were randomly divided into test group and control group.
Detailed Description
After being informed about the study and potential risks, all participants will write the informed contents. This study is a randomized controlled study co compare different treatment methods on the embryo development. Sibling eggs were randomly divided into test group and control group. Specific method of randomization: all the eggs of each subject were distributed into two dishes (dish 1 and dish 2). If the oocyte number is odd, put the extra oocyte into dish 1. Using statistical software, the two dishes were randomly treated as test group and control group. Thus, a random allocation table was generated and a separate random envelope was made for each subject. The random envelope is kept and distributed by the relevant personnel who are not involved in the screening and treatment of subjects and are authorized by the researcher. Each selected subject must open the random envelope. The subjects were subjected to routine ovulation promotion, and then the acquired oocytes and cumulus cell complexes (COCs) were obtained and fertilized in vitro. The test group oocytes were cultured with MVA, while the control oocytes were cultured without MVA. Thus, half of the eggs from each elderly infertile patient were treated with MVA.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility, Female, IVF, Reproductive Disorder, Oocyte

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
148 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
MVA treated group
Arm Type
Experimental
Arm Description
Oocytes in this groups will be cultured with MVA
Arm Title
Control group
Arm Type
No Intervention
Arm Description
Oocytes in this groups will be culture without MVA
Intervention Type
Dietary Supplement
Intervention Name(s)
Mevalproic acid
Intervention Description
Methovalerate pathway is a metabolism of cholesterol and isoprenoid synthesized from acetyl coenzyme A Pathway, which plays a key role in human health and disease, is also necessary for human cells to maintain normal functions. There are a series of important metabolic intermediates in the mevalproate pathway, such as farnesyl diphosphate and incense Folyl vanillin diphosphates, which modify proteins through isoprene, play an important role in regulating cell function. In addition, the latest research shows that valproic acid, the key metabolic intermediate of valproic acid pathway, being the synthetic precursor of cholesterol and isoprene, it can activate insulin growth factor (IGF)1-R and mTOR signals and maintain cell function by mediating histone function
Primary Outcome Measure Information:
Title
Embryo haploid rate
Description
Preimplantation genetic testing (PGT) was used to test embryo haploid rate
Time Frame
one month after oocyte retrival

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
38 Years
Maximum Age & Unit of Time
42 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 38 years ≤ age ≤ 42 years; Number of IVF/ICSI cycles ≤ 2 Exclusion Criteria: Egg donor cycle Chromosome abnormality; Adenomyosis, hysteromyoma, thin endometrium, endometriosis and other uterine diseases; Patients with repeated implantation failure
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Haixiang Sun, MD
Phone
025-83106666
Email
haixiang_sun@nju.edu.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Jie Mei, MD
Email
meijie560@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Haixiang Sun, MD
Organizational Affiliation
Center for Reproductive Medicine and Obstetrics and Gynecology, Drum Tower Hospital, Nanjing University Medical School
Official's Role
Study Director
Facility Information:
Facility Name
Reproductive Medicine Center, The affiliated Drum Towel Hospital of Nanjing University Medical School
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210008
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Haixiang Sun
Phone
025-83107188
Email
stevensunz@163.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

MVA to Improve the Pregnancy Outcome in Aged Infertility Women With Assisted Reproductive Technology

We'll reach out to this number within 24 hrs